Photocure: Results for the first quarter 2017

Our portfolio company Photocure reported a Hexvix/Cysview revenue growth of 9% to NOK 36.5 million in the first quarter of 2017 (Q1 2016: NOK 33.5), with an EBITDA of NOK 4.9 million for the Hexvix/Cysview commercial franchise. The company reported a growth of 32% for the important US market, were the company recently unveiled the […]

Targovax ASA: First quarter 2017 results

Targovax is a clinical stage company focused on developing immuno-oncology therapies to target solid tumors. On april 25th, the company announced its first quarter 2017 results.   HIGHLIGHTS FOR THE FIRST QUARTER 2017: Targovax announced encouraging top line two-year survival data from the phase I/II TG01 clinical trial in resected pancreatic cancer patients – 68%[1] […]

OncoImmunity wins prestigious EU grant

OncoImmunity AS was ranked fourth out of 250 applicants for the EU SME Instrument grant. OncoImmunity is one of the portfolio companies of the Radium Hospital Research Foundation and is developing innovative software solutions to guide the discovery of neoantigen-based personalized immunotherapies and biomarkers. “We applied for the SME instrument grant as it represents an […]

Photcure with full year report

Radforsk porfolio company Photocure reported a revenue growth of 10 % to NOK 38.1 million in the fourth quarter of 2016.

Oncoinvent closes $ 25 Million Private Placement

Our portfolio company Oncoinvent announced today the closing of a 210 MNOK (approx. 25 MUSD) private placement of ordinary shares. Financing will support development of Radspherin™, a novel radiotherapeutic treatment for peritoneal carcinomatosis. Large privately owned investment companies joining the Company as new investors include Geveran Trading Co. Ltd., Canica AS, CGS Holding AS, Helene […]

PCI Biotech awarded NOK 13.8 million from The Research Council of Norway

Our portfolio company PCI Biotech has been granted NOK 13.8 million to the project “Photochemical vaccination – novel immunotherapy concept for treatment of cancer and infectious diseases”.   The main goal of the project is to document in a proof-of-principle clinical study in cancer patients that PCI Biotech’s photochemical internalization (PCI) technology can be used […]

Oncoimmunity granted NOK 300,000 from Innovation Norway

The grant will be used to develop a software framework to predict the peptides that confer maximum immunogenicity with minimum autoimmune side-affects to a patient.

PCI Biotech and Ultimovacs awarded NOK 500,000 from Innovation Norway

The grant will be used to further development of the existing preclinical research collaboration of the two companies.